Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | KYNU | Q16719 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724195 | 0.93 | SYK (0.52) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL5724348 | 0.90 | SYK (0.57) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL5724356 | 0.90 | SYK (0.49) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL261847 | 0.89 | SYK (0.48) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL5723912 | 0.88 | CTSK (0.53) | SYKCTSLCTSSCTSBCTSK | |
| SCHEMBL263992 | 0.88 | SYK (0.47) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL262927 | 0.87 | SYK (0.47) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL263531 | 0.87 | SYK (0.47) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL264174 | 0.87 | SYK (0.47) | CTRB1SYKCTSLCTSSCTSB | |
| SCHEMBL116302 | 0.86 | SYK (0.46) | CTRB1SYKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212549-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107642-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | CTRB1 1304/4885SYK 3852/4885CTSL 2471/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | CTRB1 1304/4885SYK 3852/4885CTSL 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.